ACM
ZNTL icon

ADAR1 Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

ADAR1 Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.17M Buy
652,750
+508,114
+351% +$2.03M 0.14% 126
2026
Q1 		$338K Buy
144,636
+64,636
+81% +$167K 0.02% 228
2025
Q4 		$108K Buy
80,000
+30,000
+60% +$43.7K 0.01% 249
2025
Q3 		$75.5K Hold
50,000
– – 0.01% 203
2025
Q2 		$58K Buy
+50,000
New +$65.9K 0.01% 188

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ADAR1 Capital Management's ZNTL Position: Q2 2026 in Review

ADAR1 Capital Management increased its Zentalis Pharmaceuticals (ZNTL) stake by 351% in Q2 2026, buying an estimated $2.03M and bringing the position to 652,750 shares worth $3.17M. The position accounts for 0.14% of the portfolio, ranked #126.

ADAR1 Capital Management first reported a position in ZNTL in Q2 2025 and has held it in 5 quarters since. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • ADAR1 Capital Management held 652,750 shares of Zentalis Pharmaceuticals worth $3.17M as of Q2 2026.
  • ADAR1 Capital Management bought 508,114 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $2.03M.
  • Zentalis Pharmaceuticals made up 0.14% of ADAR1 Capital Management's portfolio in Q2 2026, its #126 holding.
  • ADAR1 Capital Management first reported a position in Zentalis Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.